The same can be said for most of these -ibs and -abs. Everyone is throwing a bunch of drugs up against COVID. Brilacidin is one of many.
It happens to have very good preclinical data but we don't know how our dosing will scale to COVID other than it was enough for ABSSSI. We also don't have much data on how much of an anti-inflammatory/immunomodulating effect this dosage will have. Brilacidin is very much a coin toss until phase 2 results confirm some meaningful efficacy. My money is on Brilacidin for the lopsided payout on a 50/50 gamble, not that it is some shoe-in treatment.
But your whole comment was beside my point: best to keep an eye on the horizon for other treatments. We've had a few scares throughout this process with the TV anointing a new oral drug every few months. None of them pan out.
B has yet to be proven in a phase 3. Labeling B a success is really a stretch... Move something (Absssi/OM/B/C) to P3 with eventual FDA approval then B would be a success. Right now, all it's done is make a few wealthy... Leo/Jane/MFO/Aspire and Kips made a ton...
News 
Market Data 
Discover 
AI
